查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1922980

医用胰岛素帮浦市场按帮浦类型、技术、糖尿病类型和通路划分－2026-2032年全球预测

Medical Insulin Pumps Market by Pump Type, Technology, Diabetes Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，医用胰岛素帮浦市场规模将达到 57.2 亿美元，到 2026 年将成长至 62.3 亿美元，复合年增长率为 9.19%，到 2032 年将达到 105.8 亿美元。

关键市场统计数据
基准年 2025 57.2亿美元
预计年份：2026年 62.3亿美元
预测年份 2032 105.8亿美元
复合年增长率 (%) 9.19%

一份简明策略指南，旨在帮助经营团队了解影响胰岛素帮浦普及和采购趋势的临床、监管和商业性因素。

胰岛素帮浦市场面临来自临床创新、不断变化的监管环境以及患者偏好转变的多重压力，因此决策者需要全面的业务概览。本文探讨了在持续皮下胰岛素输注技术日趋成熟、与持续血糖监测系统整合度不断提高以及对以患者为中心的易用性日益重视的背景下，胰岛素帮浦的市场趋势。随着医疗系统和支付方将治疗效果和成本效益置于优先地位，医疗设备功能、临床通讯协定和报销途径之间的相互作用正成为住院和门诊环境中采购和实施决策的关键驱动因素。

闭合迴路技术的进步、患者的期望以及分销模式的改变，正在从根本上改变胰岛素治疗的产品和市场推广策略。

近年来，胰岛素帮浦生态系统发生了许多变革性变化，这些变化正在重塑胰岛素帮浦生态系统，并对产品、临床和商业策略提出了新的要求。在技​​术方面，配备先进演算法和复杂闭合迴路功能的智慧胰岛素帮浦日趋成熟，模糊了治疗输送和数位疗法之间的界限，迫使製造商优先考虑软体平台、网路安全和可互通的云端生态系。随着这种向互联医疗的转变，人们对数据准确性和分析能力的期望也越来越高，以支持个人化治疗调整和人群健康监测。

评估2025年美国关税调整将如何重塑胰岛素帮相关人员的供应链结构、筹资策略和价格弹性。

美国将于2025年生效的新关税制度进一步增加了全球胰岛素帮浦供应链和相关人员商业性决策的复杂性。关税调整将影响零件采购、组装地点以及成品的最终落地成本，进而影响定价策略和利润管理。这些变化迫使製造商重新评估其区域生产基地和供应商多元化计划，以降低关税波动带来的风险，同时保持对医疗机构和零售买家的价格竞争力。

详细的細項分析表明，设备外形、糖尿病分类、技术能力和通路各自决定了不同的采用率和服务需求。

细分市场分析揭示了每种设备形式、患者群体、嵌入式技术和分销策略的不同机会和限制因素，因此需要量身定制的商业性和临床方案。依泵浦类型分析，市场可分为贴片式和管式泵浦。贴片式帮浦更受注重隐蔽性和易用性的用户青睐，而管式帮浦则更受胰岛素需求量高或有其他临床需求、需要连接硬体和更精确剂量控制的患者欢迎。这些差异会影响使用者培训计划、服务模式和保固结构。

区域比较和准入考量，重点介绍美洲、欧洲、中东和非洲以及亚太市场在临床、监管和分销方面的差异

区域趋势正深刻影响胰岛素帮相关人员的临床实务模式、监管方式和商业性重点，每个宏观区域都存在独特的驱动因素和限制因素。美洲的特点是专科医疗中心快速采用新技术，某些支付方群体高度重视基于价值的基本契约，以及蓬勃发展的数位健康整合生态系统支持远距患者管理。这些因素虽然为先进的胰岛素帮浦技术和生态系统合作创造了有利条件，但也带来了激烈的竞争压力，并提高了对上市后证据的期望。

竞争与合作的动态，透过平台整合、策略併购与价值主导的生态系统发展，塑造差异化策略。

胰岛素帮浦市场的竞争格局日益受到硬体可靠性、软体生态系统、数据整合能力和服务交付模式等因素相互作用的影响。现有设备製造商持续投资于平台级集成，将胰岛素输注硬体与血糖值监测、分析和医疗专业人员仪表板连接起来。同时，新参与企业则倾向于专注于诸如简化使用者体验、降低拥有成本和针对特定支付提案等细分优势。设备公司与数位医疗公司之间的策略联盟日益普遍，旨在加快先进功能的上市速度，并利用第三方在机器学习和使用者互动方面的专业知识。

製造商和医疗系统需要采取切实可行的策略措施，整合模组化创新、供应链韧性和以客户为中心的服务模式

产业领导者应采取整合策略，在保障营运韧性和商业性柔软性的同时，加速以病人为中心的创新。优先采用模组化产品架构，将核心交付机制与可升级的软体元件分离，使供应商能够迭代功能并快速部署监管更新。投资于互通性标准和开放API，可实现与医院电子健康记录、远端监控平台和第三方分析解决方案的无缝集成，从而提高临床应用率。

稳健的混合方法研究通讯协定，整合了专家访谈、证据三角验证和情境分析，以确保分析的严谨性和实际相关性。

本执行摘要的调查方法整合了定性和定量数据，并透过结构化、透明的流程来最大限度地提高研究的有效性和可靠性。主要研究包括对临床医生、采购人员、支付方和行业高管的访谈，以了解他们对设备可用性、临床整合和采购考虑等方面的真实观点。在条件允许的情况下，我们会透过现场考察和设备可用性评估来补充这些访谈数据，从而验证相关人员的认知与实际操作情况。

综合分析揭示了技术、证据和营运韧性之间的关键交汇点，从而阐明了决定未来胰岛素输送成功与否的关键因素。

总之，胰岛素帮浦市场环境正进入一个关键阶段，技术能力、卓越服务和策略适应性将决定其长期成功。智慧帮浦技术和互通性的进步为改善临床疗效和患者生活品质提供了明确的机会，但要实现这些益处，需要精心协调产品设计、证据产生和通路策略。关税驱动的供应链重组和支付方期望的转变，凸显了营运韧性和透明价值沟通的重要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依帮浦类型分類的医用胰岛素帮浦市场

  • 补片泵浦
  • 管泵

9. 以技术分類的医用胰岛素帮浦市场

  • 传统泵浦
  • 智慧泵浦

第十章 依糖尿病类型分類的医用胰岛素帮浦市场

  • 1型糖尿病
  • 2型糖尿病

第十一章 依分销管道分類的医用胰岛素帮浦市场

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 医疗胰岛素帮浦市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 依组别分類的医用胰岛素帮浦市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国医用胰岛素帮浦市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国医用胰岛素帮浦市场

第十六章：中国医用胰岛素帮浦市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AgVa Healthcare Pvt Ltd
  • AMF Medical SA
  • Becton Dickinson and Company
  • Beta Bionics, Inc.
  • Cane SpA
  • Debiotech SA
  • DreaMed Diabetes Ltd.
  • EOFlow Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Insulet Corporation
  • Medtronic plc
  • Medtrum Technologies
  • MicroPort Scientific Corporation
  • Smiths Group plc
  • SOOIL Development Co., Ltd.
  • Tandem Diabetes Care, Inc.
  • Terumo Corporation
  • ViCentra BV
  • Ypsomed AG
Product Code: MRR-867BED9A9E9C

The Medical Insulin Pumps Market was valued at USD 5.72 billion in 2025 and is projected to grow to USD 6.23 billion in 2026, with a CAGR of 9.19%, reaching USD 10.58 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.72 billion
Estimated Year [2026] USD 6.23 billion
Forecast Year [2032] USD 10.58 billion
CAGR (%) 9.19%

A concise strategic orientation for executives to understand clinical, regulatory, and commercial forces reshaping insulin pump adoption and procurement dynamics

The insulin pump market is experiencing convergent pressures from clinical innovation, regulatory evolution, and shifting patient preferences that demand an integrated executive overview for decision-makers. This introduction situates readers within a landscape defined by technological maturity in continuous subcutaneous insulin delivery, increasing integration with continuous glucose monitoring systems, and rising emphasis on patient-centered usability. As health systems and payers prioritize outcomes and cost-effectiveness, the interplay between device features, clinical protocols, and reimbursement pathways is becoming a primary driver of purchasing and adoption decisions across inpatient and outpatient settings.

Clinicians, procurement teams, and strategic planners require a concise framing of the core variables influencing adoption: device ergonomics, interoperability with digital platforms, lifecycle management and service models, and regulatory compliance across jurisdictions. These variables shape not only product development roadmaps but also distribution approaches and post-market surveillance strategies. The introduction clarifies the operational stakes for manufacturers and health-system partners alike, highlighting where near-term operational shifts can yield durable competitive advantage.

Finally, this section sets the tone for the subsequent analysis by establishing a common vocabulary for segmentation, regional dynamics, and competitive behavior. It underscores the need for evidence-driven decisions that balance clinical efficacy, patient experience, and commercial viability while preparing leaders to interpret deeper insights in the sections that follow.

How converging advances in closed-loop technology, patient expectations, and distribution models are fundamentally altering product and go-to-market strategies in insulin therapy

Recent years have seen several transformative shifts that are redefining the insulin pump ecosystem and creating new imperatives for product, clinical, and commercial strategy. At the technology level, the maturation of smart pumps with advanced algorithms and sophisticated closed-loop capabilities has blurred the lines between therapy delivery and digital therapeutics, prompting manufacturers to prioritize software platforms, cybersecurity, and interoperable cloud ecosystems. This movement toward connected care is accompanied by heightened expectations for data fidelity and analytics, which support personalized therapy adjustments and population health monitoring.

Concurrently, patient expectations are changing: a growing cohort of users is seeking discreet form factors and simplified workflows that reduce cognitive burden. This trend favors patch-style delivery systems while preserving the option for tubed pumps in more complex clinical scenarios. The distribution and service models are also shifting as online pharmacies and direct-to-consumer channels gain prominence alongside traditional hospital pharmacies and retail networks, necessitating new logistics, onboarding, and remote support capabilities.

Regulators and payers are increasingly focused on evidence generation that demonstrates real-world outcomes and cost-effectiveness. This emphasis has incentivized partnerships between device makers, academic institutions, and health systems to run pragmatic studies and registries. Taken together, these shifts are not isolated; they interact to create a landscape where agility in technology integration, human-centered design, and evidence-based commercialization are critical for sustained success.

Assessing how United States tariff adjustments in 2025 are reshaping supply chain configurations, sourcing strategies, and pricing resilience for insulin pump stakeholders

The introduction of new tariff regimes in the United States in 2025 has introduced another layer of complexity into the global supply chain and commercial calculus for insulin pump stakeholders. Tariff adjustments impact sourcing decisions for components, assembly locations, and the overall landed cost of finished systems, which in turn affects pricing strategies and margin management. These changes have prompted manufacturers to reassess regional manufacturing footprints and supplier diversification plans to mitigate exposure to tariff volatility and maintain competitive pricing structures for institutional and retail purchasers.

Beyond direct cost effects, tariff shifts influence strategic decisions about where to locate high-value activities such as software development, quality assurance, and final assembly. Companies with vertically integrated operations or near-shore partners have found opportunities to buffer tariff impacts, while those dependent on single-source international suppliers face greater pressure to redesign bills of materials or pursue alternative components. Additionally, reimbursement negotiations and procurement tenders may be more sensitive to price fluctuations; stakeholders must therefore strengthen cost-transparency efforts and provide robust clinical and economic evidence to sustain payer and provider relationships.

Operationally, supply chain resilience has become a focal point. Firms are accelerating dual-sourcing strategies, increasing inventory visibility, and investing in advanced planning systems to reduce lead-times and prevent stock disruptions. These adaptations are essential not only for commercial continuity but also for preserving patient access to essential insulin delivery technologies across care settings.

In-depth segmentation intelligence revealing how device form factors, diabetes classifications, technological capabilities, and channel pathways define distinct adoption and service imperatives

Segmentation analysis reveals nuanced opportunities and constraints across device formats, patient populations, embedded technologies, and channel strategies, each demanding tailored commercial and clinical approaches. When examined by pump type, the market differentiates between patch pumps and tubed pumps, with patch designs appealing to users prioritizing discretion and ease of use while tubed systems often serve patients with higher insulin requirements or clinical needs that benefit from tethered hardware and more granular dosing control. These distinctions influence user training programs, service models, and warranty structures.

Considering diabetes type, the needs of individuals with Type 1 Diabetes often emphasize automated insulin delivery and tighter glycemic control, whereas those with Type 2 Diabetes may prioritize simplicity, affordability, and incremental therapy intensification. This divergence affects messaging, clinical support pathways, and partnerships with endocrinology networks. From a technology perspective, the contrast between conventional pumps and smart pumps highlights differing value propositions: conventional pumps emphasize reliable mechanical delivery and cost-effectiveness, while smart pumps integrate decision-support, connectivity, and software-driven features that enable remote monitoring and data-driven therapy optimization.

Distribution channel dynamics further shape adoption. Hospital pharmacies remain central for inpatient and credentialed outpatient initiation, whereas online pharmacies present opportunities for direct consumer fulfillment and subscription models. Retail pharmacies deliver convenience and local support but require different stocking and education strategies. For manufacturers and channel partners, aligning product configurations, training curricula, and support services to the intersection of pump type, diabetes type, technology sophistication, and chosen distribution paths is essential for maximizing adoption and long-term adherence.

Comparative regional dynamics and entry considerations highlighting clinical, regulatory, and distribution nuances across the Americas, EMEA, and Asia-Pacific markets

Regional dynamics exert a strong influence on clinical practice patterns, regulatory approaches, and commercial priorities for insulin pump stakeholders, with each macro-region presenting distinct drivers and constraints. In the Americas, the ecosystem is characterized by rapid technology adoption among specialist centers, a strong emphasis on value-based contracting in select payer segments, and an active ecosystem of digital health integration that supports remote patient management. These factors create fertile ground for advanced pump technologies and ecosystem partnerships but also introduce intense competitive pressures and higher expectations for post-market evidence.

Across Europe, Middle East & Africa, the picture is heterogeneous: certain European markets emphasize strict health-technology assessments and centralized procurement processes that require robust cost-effectiveness data, while markets across the Middle East and Africa present opportunities for incremental access expansion, local partnerships, and tailored training initiatives to support decentralized care delivery. Regulatory harmonization efforts within the region can simplify market entry, but manufacturers still need to navigate localized reimbursement policies and supply chain challenges.

In the Asia-Pacific region, growth drivers include rising prevalence of diabetes, expanding private and public healthcare capacity, and a strong interest in mobile-enabled care models. However, success in these markets often depends on localized product customization, tiered pricing strategies, and partnerships with regional distributors and healthcare systems that can manage training and long-term patient support. Across all regions, aligning clinical evidence generation, regulatory pathways, and distribution strategies to regional realities is critical for sustainable market penetration and patient access.

Competitive and partnership dynamics shaping differentiation strategies through platform integration, strategic M&A, and value-driven ecosystem development

Competitive dynamics in the insulin pump landscape are increasingly defined by the interplay of hardware reliability, software ecosystems, data integration capabilities, and service delivery models. Established device manufacturers continue to invest in platform-level integration that links insulin delivery hardware with glucose sensing, analytics, and clinician-facing dashboards, while newer entrants often focus on niche advantages such as simplified user experience, lower cost of ownership, or specialized payer propositions. Strategic collaborations between device firms and digital health companies are becoming more commonplace as players seek to accelerate time-to-market for advanced features and leverage third-party expertise in machine learning and user engagement.

Partnerships and M&A activity are also reshaping competitive positioning. Companies are pursuing acquisitions that fill gaps in connectivity stacks, extend regulatory footprints, or add complementary distribution channels. In parallel, strategic alliances with healthcare systems, specialty pharmacies, and patient advocacy groups are proving valuable for establishing real-world registries and demonstrating long-term outcomes. Those firms that can demonstrate a coherent product-service ecosystem-combining robust hardware, intuitive software, reliable logistics, and outcomes evidence-are more likely to secure preferential placement in institutional formularies and payer-covered pathways.

Operational excellence remains a differentiator. Firms that invest in scalable manufacturing, regulatory rigor, and quality management systems while maintaining agile product development cycles are better positioned to respond to shifting clinical guidance and emergent cybersecurity requirements. For incumbents and challengers alike, the path to differentiation lies in delivering measurable clinical benefits alongside seamless user experiences and dependable support infrastructures.

Actionable strategic imperatives for manufacturers and health systems to align modular innovation, supply chain resilience, and customer-centric service models

Industry leaders should adopt an integrated playbook that accelerates patient-centric innovation while protecting operational resilience and commercial flexibility. Prioritizing modular product architectures that separate core delivery mechanics from upgradable software components will allow vendors to iterate features and deploy regulatory updates more rapidly. Investing in interoperability standards and open APIs can broaden clinical adoption by enabling seamless integration with hospital electronic medical records, remote monitoring platforms, and third-party analytics solutions.

Supply chain and manufacturing strategies must emphasize redundancy and geographic diversification to mitigate tariff and trade disruptions. Concurrently, commercial teams should develop differentiated value propositions for payers and providers that highlight not only clinical performance but also reductions in total cost of care through decreased hypoglycemia events, fewer emergency visits, and improved long-term outcomes. Providers will respond to clear evidence of clinical and operational benefit, so building pragmatic registries and real-world evidence programs that can be communicated in clinician-friendly formats is essential.

Finally, customer experience should be treated as a strategic priority: streamlined onboarding, accessible remote training, and responsive post-sale support underpin adherence and long-term retention. Leaders should also explore subscription and service-based pricing models that align incentives between manufacturers, payers, and health systems, enabling predictable revenue streams while lowering upfront barriers to access for patients and institutions.

Robust mixed-method research protocols integrating expert interviews, evidence triangulation, and scenario analysis to ensure analytical rigor and practical relevance

The research methodology underpinning this executive summary synthesizes qualitative and quantitative inputs through a structured, transparent process designed to maximize validity and reliability. Primary research comprises targeted interviews with clinicians, procurement leads, payers, and industry executives to capture real-world perspectives on device usability, clinical integration, and purchasing considerations. These interviews are supplemented by observational inputs from site visits and device usability assessments where feasible, enabling triangulation between stakeholder perceptions and operational realities.

Secondary research includes systematic review of regulatory guidance, clinical literature, patent filings, and public company disclosures to map technology roadmaps and compliance obligations. Evidence synthesis applies data triangulation techniques that reconcile insights from multiple sources and identify consistent themes and divergence points. Wherever possible, claims and interpretations are cross-validated against peer-reviewed clinical evidence and regulatory documentation to ensure factual accuracy and contextual relevance.

Analytical approaches include scenario analysis to explore the implications of tariff shifts and technology adoption trajectories, along with sensitivity testing of key operational assumptions. Expert advisory input has been leveraged throughout to challenge assumptions, validate findings, and ensure the final recommendations are practical and actionable for industry stakeholders.

Concluding synthesis identifying the critical intersections of technology, evidence, and operational resilience that will determine future success in insulin delivery

In conclusion, the insulin pump landscape is entering a phase where technological capability, service excellence, and strategic adaptability determine long-term success. Advances in smart pump technology and interoperability present clear opportunities to improve clinical outcomes and patient quality of life, yet realizing these benefits requires careful alignment of product design, evidence generation, and channel strategy. The combined effects of tariff-driven supply chain recalibration and shifting payer expectations underscore the importance of operational resilience and transparent value communication.

Stakeholders who prioritize modular architectures, invest in real-world outcomes programs, and build flexible distribution and support models will be better positioned to convert technological potential into sustained adoption. Likewise, collaborations across industry, healthcare providers, and digital health partners will accelerate the development of integrated solutions that address both clinical efficacy and patient experience. The path forward is not without complexity, but deliberate, evidence-driven strategies provide a clear route to advancing care while achieving commercial objectives.

Taken together, these conclusions point to a pragmatic agenda for leaders: focus on interoperable innovation, strengthen supply chain and value demonstration capabilities, and enhance customer experience to secure durable market relevance and improve patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Medical Insulin Pumps Market, by Pump Type

  • 8.1. Patch Pumps
  • 8.2. Tubed Pumps

9. Medical Insulin Pumps Market, by Technology

  • 9.1. Conventional Pumps
  • 9.2. Smart Pumps

10. Medical Insulin Pumps Market, by Diabetes Type

  • 10.1. Type 1 Diabetes
  • 10.2. Type 2 Diabetes

11. Medical Insulin Pumps Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Medical Insulin Pumps Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Medical Insulin Pumps Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Medical Insulin Pumps Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Medical Insulin Pumps Market

16. China Medical Insulin Pumps Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AgVa Healthcare Pvt Ltd
  • 17.6. AMF Medical SA
  • 17.7. Becton Dickinson and Company
  • 17.8. Beta Bionics, Inc.
  • 17.9. Cane S.p.A.
  • 17.10. Debiotech S.A.
  • 17.11. DreaMed Diabetes Ltd.
  • 17.12. EOFlow Co., Ltd.
  • 17.13. F. Hoffmann-La Roche Ltd.
  • 17.14. Insulet Corporation
  • 17.15. Medtronic plc
  • 17.16. Medtrum Technologies
  • 17.17. MicroPort Scientific Corporation
  • 17.18. Smiths Group plc
  • 17.19. SOOIL Development Co., Ltd.
  • 17.20. Tandem Diabetes Care, Inc.
  • 17.21. Terumo Corporation
  • 17.22. ViCentra B.V.
  • 17.23. Ypsomed AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MEDICAL INSULIN PUMPS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MEDICAL INSULIN PUMPS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MEDICAL INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MEDICAL INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY PATCH PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY PATCH PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY PATCH PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TUBED PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TUBED PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TUBED PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY CONVENTIONAL PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY CONVENTIONAL PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY CONVENTIONAL PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY SMART PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY SMART PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY SMART PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. AMERICAS MEDICAL INSULIN PUMPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 35. AMERICAS MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. AMERICAS MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. NORTH AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. NORTH AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. NORTH AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. LATIN AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. LATIN AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. LATIN AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. EUROPE, MIDDLE EAST & AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 50. EUROPE, MIDDLE EAST & AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. MIDDLE EAST MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. MIDDLE EAST MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. ASEAN MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASEAN MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASEAN MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. GCC MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GCC MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. GCC MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. GCC MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. GCC MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPEAN UNION MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPEAN UNION MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPEAN UNION MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. BRICS MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. BRICS MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. BRICS MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. G7 MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. G7 MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. G7 MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. G7 MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. G7 MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NATO MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NATO MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NATO MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. NATO MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. NATO MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MEDICAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. UNITED STATES MEDICAL INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. UNITED STATES MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. UNITED STATES MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. CHINA MEDICAL INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. CHINA MEDICAL INSULIN PUMPS MARKET SIZE, BY PUMP TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. CHINA MEDICAL INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA MEDICAL INSULIN PUMPS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA MEDICAL INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)